Mode
Text Size
Log in / Sign up
N/A N=113 Randomized Single-blind Treatment

HRV Biofeedback in Pain Patients

Chronic Neuromuscular Pain

Enrolled (actual)
113
Serious AEs
0.9%
Results posted
Jun 2021
Primary outcome: Primary: Pain Interference Rating, Measured With the Brief Pain Inventory (BPI) — 7.2; 7.4; 6.2; 6.9 score on a scale — p=<0.01

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
active heart rate variability biofeedback training (Behavioral); sham HRVB training (Behavioral)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Sep 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Interference Rating, Measured With the Brief Pain Inventory (BPI)
7.2; 7.4; 6.2; 6.9 <0.01 sig
PRIMARY
Perceived Stress Scale (PSS)
22; 23; 20; 21 0.87
PRIMARY
Heart Rate Variability Coherence Ratio
0.18; 0.17; 0.52; 0.20 <0.01 sig

Summary

Pain initiates a stress response that increases sympathetic output and leads to autonomic imbalance. Heart rate variability (HRV) is a easy to perform, valid measure of autonomic function. HRV biofeedback (HRV-B) is a novel biobehavioral procedure in which patients learn to restore autonomic balance by developing 'HRV Coherence'. Patients in HRV Coherence have improved mood and cognition. The investigators' pilot study showed that HRV-B alleviated chronic pain and stress among Veteran Pain Clinic patients. HRV-B thus has a pivotal role in managing pain. The proposed project is a randomized, sham-controlled, biobehavioral intervention with HRV-B to test the hypotheses that HRV-B increases HRV coherence and reduces pain, stress, fatigue, insomnia and depression and improves sleep, activity, and cognition in Veterans with chronic neuromuscular pain. The investigators hypothesize that HRV-B will (1) reduce self-reported pain and stress ratings, (2) improve objective measures of actigraphic sleep parameters (sleep latency, duration, efficiency, fragmentation), rest/activity rhythms (dichotomy index, interdaily stability) and cognitive function (reaction time, attention); and (3) alleviate self-reported fatigue and depression symptoms. Patients from two groups will be randomized to the investigators' previously established HRV-B or sham protocol (n=40 each), and will complete a baseline assessment, 6 weekly training sessions, a post-training assessment, and 4-week and 8-week follow-up evaluations post-training. Portable, hand-held, data-logging devices will be used to practice attaining HRV coherence at home by the active HRV-B training group, while those in the sham training group will get a 'stress squeeze ball'. Standard methods will quantify HRV coherence and other HRV measures, and validated instruments will be used to assess pain, stress, fatigue, insomnia, depression, and cognitive function. Wrist actigraphy will be used to objectively characterize insomnia via continuous recordings collected 24-hrs/day over three 1-week periods (pre-training, post-training, and at the 4 week follow-up assessments. Tests measuring attention and reaction time will assess changes in cognitive performance. Data analyses will apply linear models for repeated measures to evaluate the effect of HRV-B on study outcomes, and on treatment persistence, after adjusting for confounding factors. This study will be the first to examine HRV-B for pain management among Veteran chronic pain patients.

Eligibility Criteria

Inclusion Criteria

  • are a Veteran between age 18 or older
  • have chronic, non-malignant, neuro-musculoskeletal pain

Exclusion Criteria

  • a history of arrhythmia requiring medication or hospitalization
  • a pacemaker or automatic implantable cardioverter-defibrillator
  • a history of ischemic heart disease, heart transplant, cardiovascular surgery within 1 year
  • congestive heart failure
  • uncontrolled hypertension
  • an active prescription for certain heart medications
  • a history of seizures or use of antiseizure or anticonvulsant medication
  • moderate or severe head injury or stroke
  • evidence of active substance abuse or dependence (alcohol or tobacco use is not be an exclusion, participants will be asked to provide information about these behaviors in the investigators' questionnaire)
  • a history of bipolar, psychotic, panic or obsessive-compulsive disorder (note: depression is an exclusion)
  • cognitive impairment (dementia), neurocognitive deficits, or a central nervous system or neurological disorder (e.g., Gulf War Syndrome)
  • a current or pending worker compensation claim or personal injury litigation related to the participants' symptoms
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02426476). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search